Bristol Myers Squibb that the U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
BioCina, a leading contract development and manufacturing organization (CDMO) that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite.
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, that it will unveil its new Daikyo Crystal Zenith® 2.25m.
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, its participation in the American Society of Gene & Cell Therapy (ASGCT).
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, the appointment of Meredith Manning to President of the Americas, effective immediately.
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.
STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms.
Bionter AG, experts in sub-visible particle testing, the completion of a $3 million Series Seed financing from Dynamk Capital.
Abbott (NYSE: ABT), CamDiab and Ypsomed that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes.
Alercell,that it will begin distributing a Leukemia Fusion Gene Screening and Genotyping Kit created and manufactured by Zeesan, a longtime partner of Alercell.